The present inventor has found that glioblastoma cells respond in unique ways to prolactin (Prl) receptor antagonists. The reaction of glioblastoma cells to treatment with Prl receptor antagonists is based on the presence and function of Prl receptors in glioblastomas and the activity can be used for treatment of glioblastomas and other neoplasms of the CNS.